|
1
|
Eis-Hübinger AM, Schmidt DS and Schneweis
KE: Anti-glycoprotein B monoclonal antibody protects T
cell-depleted mice against herpes simplex virus infection by
inhibition of virus replication at the inoculated mucous membranes.
J Gen Virol. 74:379–385. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sherwood JK, Zeitlin L, Whaley KJ, Cone RA
and Saltzman M: Controlled release of antibodies for long-term
topical passive immunoprotection of female mice against genital
herpes. Nat Biotechnol. 14:468–471. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Milligan GN, Dudley-McClain KL, Chu CF and
Young CG: Efficacy of genital T cell responses to herpes simplex
virus type 2 resulting from immunization of the nasal mucosa.
Virology. 318:507–515. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuklin N, Daheshia M, Karem K, Manickan E
and Rouse BT: Induction of mucosal immunity against herpes simplex
virus by plasmid DNA immunization. J Virol. 71:3138–3145.
1997.PubMed/NCBI
|
|
5
|
Manickan E, Rouse RJ, Yu Z, Wire WS and
Rouse BT: Genetic immunization against herpes simplex virus.
Protection is mediated by CD4+ T lymphocytes. J Immunol.
155:259–265. 1995.PubMed/NCBI
|
|
6
|
McDermott MR, Goldsmith CH, Rosenthal KL
and Brais LJ: T lymphocytes in genital lymph nodes protect mice
from intravaginal infection with herpes simplex virus type 2. J
Infect Dis. 159:460–466. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoshino Y, Dalai SK, Wang K, Pesnicak L,
Lau TY, Knipe DM, Cohen JI and Straus SE: Comparative efficacy and
immunogenicity of replication-defective, recombinant glycoprotein,
and DNA vaccines for herpes simplex virus 2 infections in mice and
guinea pigs. J Virol. 79:410–418. 2005. View Article : Google Scholar :
|
|
8
|
Ramachandran S and Kinchington PR:
Potential prophylactic and therapeutic vaccines for HSV infections.
Curr Pharm Des. 13:1965–1973. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harandi AM: The potential of
immunostimulatory CpG DNA for inducing immunity against genital
herpes: Opportunities and challenges. J ClinVirol. 30:207–210.
2004.
|
|
10
|
Kwant A and Rosenthal KL: Intravaginal
immunization with viral subunit protein plus CpG
oligodeoxynucleotides induces protective immunity against HSV-2.
Vaccine. 22:3098–3104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harandi AM: The potential of
immunostimulatory CpG DNA for inducing immunity against genital
herpes: Opportunities and challenges. J Clin Virol. 30:207–210.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spear PG and Roizman B: Proteins specified
by herpes simplex virus. V. Purification and structural proteins of
the herpesvirion. J Virol. 9:143–159. 1972.PubMed/NCBI
|
|
13
|
Hong Y, Yang LH, Chen Y, Jing L, Jiang JH
and Wang YT: Immune response induced by herpes simplex virus-2 DNA
vaccine in mice. Chin J Publ Health. 19:1079–1080. 2003.
|
|
14
|
Sambrook J and Russell D: Molecular
Cloning: A Laboratory Manual. 3rd Edition. Cold Spring Harbor
Laboratory Press; New York: pp. 1632001
|
|
15
|
Zhou C, Cao CL, Fan JY and Yang HL:
Prokaryotic expression of full length HSV-2 gD antigen and its
antienicity. J Pract Med. 24:1668–1670. 2008.
|
|
16
|
Prince HE, Arens L and Kleinman SH: CD4
and CD8 subsets defined by dual-color cytofluorometry which
distinguish symptomatic from asymptomatic blood donors seropositive
for human immunodeficiency virus. Diagn Clin Immunol. 5:188–193.
1987.PubMed/NCBI
|
|
17
|
Görander S, Ekblad M, Bergström T and
Liljeqvist JÅ: Anti-glycoprotein g antibodies of herpes simplex
virus 2 contribute to complete protection after vaccination in mice
and induce antibody-dependent cellular cytotoxicity and
complement-mediated cytolysis. Viruses. 6:4358–4372. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Awasthi S, Balliet JW, Flynn JA, Lubinski
JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, et
al: Protection provided by a herpes simplex virus 2 (HSV-2)
glycoprotein C and D subunit antigen vaccine against genital HSV-2
infection in HSV-1-seropositive guinea pigs. J Virol. 88:2000–2010.
2014. View Article : Google Scholar :
|
|
19
|
Delagrave S, Hernandez H, Zhou C,
Hamberger JF, Mundle ST, Catalan J, Baloglu S, Anderson SF,
DiNapoli JM, Londoño-Hayes P, et al: Immunogenicity and efficacy of
intra-muscular replication-defective and subunit vaccines against
herpes simplex virus type 2 in the mouse genital model. PLoS One.
7:e467142012. View Article : Google Scholar
|
|
20
|
Sin JI, Kim JJ, Arnold RL, Shroff KE,
McCallus D, Pachuk C, McElhiney SP, Wolf MW, Pompa-de Bruin SJ,
Higgins TJ, et al: IL-12 gene as a DNA vaccine adjuvant in a herpes
mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated
protective immunity against herpes simplex virus-2 challenge. J
Immunol. 162:2912–2921. 1999.PubMed/NCBI
|
|
21
|
Eo SK, Lee S, Chun S and Rouse BT:
Modulation of immunity against herpes simplex virus infection via
mucosal genetic transfer of plasmid DNA encoding chemokines. J
Virol. 75:569–578. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee S, Gierynska M, Eo SK, Kuklin N and
Rouse BT: Influence of DNA encoding cytokines on systemic and
mucosal immunity following genetic vaccination against herpes
simplex virus. Microbes Infect. 5:571–578. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haynes JR, Arrington J, Dong L, Braun RP
and Payne LG: Potent protective cellular immune responses generated
by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile
enterotoxin. Vaccine. 24:5016–5026. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sato Y, Roman M, Tighe H, Lee D, Corr M,
Nguyen MD, Silverman GJ, Lotz M, Carson DA and Raz E:
Immunostimulatory DNA sequences necessary for effective intradermal
gene immunization. Science. 273:352–354. 1996. View Article : Google Scholar : PubMed/NCBI
|
